Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Eli Lilly Will Not Seek FDA Approval for Osteoporosis Drug

By Pharmaceutical Processing | August 19, 2009

NEW YORK (AP) — Eli Lilly & Co. said Tuesday it will not seek FDA approval for its developing postmenopausal osteoporosis drug because of certain study results and safety concerns. The company said the drug met its late-stage study goals of reducing the risk of vertebral fracture and invasive breast cancer, but failed to meet a variety of secondary goals, such as cognitive function and non-vertebral fractures. Meanwhile, there were some serious safety concerns over increased risk of blood clots and gynecological-related events. The five-year study involved 9,354 postmenopausal women. “The results of arzoxifene’s Generations study serve as a reminder of the high risks associated with pharmaceutical innovation,” said Eli Lilly Chairman and CEO John Lechleiter, in a statement. The Indianapolis company expects to book a third-quarter charge of about 3 to 4 cents per share associated with costs for shutting down the program. Still, the company expects full-year profit between $4.20 and $4.30 per share, excluding charges. Analysts on average expect a profit of $1.01 per share for the third quarter and $4.28 per share for the full year.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE